ASH 2021 Conference Coverage on VuMedi


 

ASH 2021: Outcomes of Patients Treated With CPX-351 as 1L Therapy for AML Based on Their Antecedent History of Myeloid Malignancy

12 views
December 22, 2021
Comments 0
Login to view comments. Click here to Login